PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
Data regarding optimal treatment for extended-spectrum beta-lactamase (ESBL) producing
Enterobacterales bloodstream infection are lacking. Observational studies show conflicting
results when comparing treatment with combination beta-lactam-beta-lactamase inhibitor and
carbapenems. The investigators aim to evaluate the effect of definitive treatment with
meropenem vs. piperacillin-tazobactam on the outcome of patients with bacteremia due to
cephalosporin-non-susceptible Enterobacteriaceae. The investigators hypothesize that
piperacillin-tazobactam is non-inferior to meropenem.
Phase:
Phase 4
Details
Lead Sponsor:
Rambam Health Care Campus
Collaborators:
Rabin Medical Center The Chaim Sheba Medical Center
Treatments:
Meropenem Piperacillin Piperacillin, Tazobactam Drug Combination Tazobactam